Categories: Mental health

Effectiveness of pharmacological and non-pharmacological interventions for treatment-resistant depression in older patients: a systematic review and meta-analysis

Background

Depression in older adults is often undertreated. A 2011 systematic review of treatments for treatment-resistant depression (TRD) in older adults identified one placebo-controlled randomised controlled trial (RCT). We aimed to update this review, synthesising evidence for the effectiveness of treatments for TRD in older people.


Methods

We systematically searched electronic databases (PubMed, Cochrane, Web of Science) from 9 January 2011 through 10 December 2023 (updating our search on 7 January 2024 for RCTs investigating TRD therapies in adults aged ≥55 years, defining treatment resistance as ≥1 unsuccessful treatment. We assessed bias with the Cochrane Risk of Bias (RoB) 2 tool, meta-analysed remission rates and evaluated evidence using GRADE (Grading of Recommendations Assessment, Development, and Evaluation) criteria.


Results

14 studies (11 newly identified, 3 from previous review) involving 1196 participants (mean age 65.0, male/female 548/648) met the inclusion criteria; 10 were placebo controlled and 4 were rated as low RoB. The pooled proportion of participants in intervention arms remitting was 0.35 (17 arms; 95% CI=0.26; 0.45). Relative to placebo, intervention participants were more likely to remit (9 studies; OR 2.42 (95% CI=1.49; 3.92)). Relative to controls, remission rates favoured ketamine (n=3; OR 2.91 (1.11; 7.65)), with a trend towards transcranial magnetic stimulation (TMS) (n=3; 1.99 (0.71; 5.61)), and in single placebo-controlled studies, selegiline, aripiprazole augmentation, pharmacogenetic-guided prescribing (PGP) and cognitive remediation favoured interventions.


Conclusions

We identified weak evidence that ketamine therapy and aripiprazole augmentation, and very weak evidence that TMS, PGP and cognitive remediation increased remission. Lack of evidence regarding routinely prescribed antidepressants and psychosocial treatments is problematic, requiring clinicians to extend evidence from younger populations.


PROSPERO registration number

CRD42023494513.

prince

Share
Published by
prince

Recent Posts

Chronotherapeutic considerations of benzodiazepine administration for agitation management in the emergency department

Objective Agitation in the emergency department (ED) affects up to 2.6% of encounters, posing significant…

2 days ago

Lack of neuropsychological effects following short-term subcallosal cingulate gyrus deep brain stimulation in treatment-resistant depression: a randomised crossover study

Background The subcallosal cingulate gyrus (SCG) is integral to cognitive function and mood regulation. Open-label…

6 days ago

Advancing mixed methods in mental health research

In the mental health research field, there is a need for effective and robust methodological…

6 days ago

Bridging assessment and treatment for repeat suicidality in prisons: development and validation of a risk model

Background Suicidal thoughts and behaviours are common in people in prison and associated with poor…

6 days ago

How Much Protein Is in Avocado Toast? (And Easy Ways to Boost It!)

I love a good avocado toast—simple, delicious, and healthy. But until recently, I had no…

2 weeks ago